You've got the drugs.
We've got the drugs.
Let's make lots of money.
-- Pharma remix of "Opportunities," Pet Shop Boys
Eli Lilly
Both companies will contribute two drugs to the partnership, and Boehringer has the option to add Lilly's anti-TGF-beta antibody at a later date. The deal calls for payments in both directions when drugs reach certain regulatory milestones. Boehringer could get up to about $810 million for its compounds. Lilly is potentially due $650 million for its two drugs, with as much as an additional $525 million if Boehringer opts to bring in Lilly's anti-TGF-beta antibody and it makes it to market.
Boehringer is contributing more to the partnership, given the late stage its products are in, so Lilly will initially pay around $390 million to join the party. Lilly could use some late-stage assets given its coming patent cliff, so making the additional upfront payment is a necessary evil.
I really like the structure of the deal, as it lowers the risk for both companies, but the milestone payments allow them to retain some upside. By owning half of four drugs instead of all of two drugs, they're splitting the development risk into a bigger pie.
Pfizer
That kind of structure might not have worked well for Lilly, though, since it jointly markets Byetta with Amylin Pharmaceuticals
More stock math: 3 stocks our experts like plus a 4-star stock equals 7 stocks that could hit the jackpot.
